Cargando…
Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis
Endoscopic interventional is a commonly used treatment method for idiopathic chronic pancreatitis. Serine protease inhibitor Kazal type 1 (SPINK1) 194+2T>C mutation is most frequently observed in Chinese pancreatitis patients and influences the clinical course of idiopathic chronic pancreatitis p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058975/ https://www.ncbi.nlm.nih.gov/pubmed/26632706 http://dx.doi.org/10.1097/MD.0000000000002046 |
_version_ | 1782459348869447680 |
---|---|
author | Sun, Chang Liu, Mu-Yun Liu, Xiao-Gang Hu, Liang-Hao Xia, Tian Liao, Zhuan Li, Zhao-Shen |
author_facet | Sun, Chang Liu, Mu-Yun Liu, Xiao-Gang Hu, Liang-Hao Xia, Tian Liao, Zhuan Li, Zhao-Shen |
author_sort | Sun, Chang |
collection | PubMed |
description | Endoscopic interventional is a commonly used treatment method for idiopathic chronic pancreatitis. Serine protease inhibitor Kazal type 1 (SPINK1) 194+2T>C mutation is most frequently observed in Chinese pancreatitis patients and influences the clinical course of idiopathic chronic pancreatitis patients. We conducted this study to determine the impacts of this mutation on the outcome of endoscopic treatments. In this study, we enrolled 423 patients. Among them, 101 idiopathic chronic pancreatitis patients without other relevant mutations had a successful endoscopic procedure and completed follow-up. Clinical characteristics including Izbicki pain score, exocrine and endocrine function, were evaluated. Genetic sequencing was conducted to detect SPINK1 194+2T>C mutations. The c.194+2T>C mutation was found in 58 (57.43%) patients. Factors relevant to pain relief are c.194+2T>C mutation (P = 0.011), severe pain before treatment (P = 0.005), and necessary subsequent endoscopic treatments (P < 0.001). More patients with the intronic mutation had deteriorated endocrine function (P = 0.001) relative to those patients without the mutation. Patients carrying the c.194+2T>C mutation were less likely to achieve pain relief through endoscopic treatments. They also have a higher risk of endocrine function deterioration. SPINK1 c.194+2T>C mutation may be applied as a pretreatment predictor in idiopathic chronic pancreatitis patients. |
format | Online Article Text |
id | pubmed-5058975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-50589752016-11-01 Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis Sun, Chang Liu, Mu-Yun Liu, Xiao-Gang Hu, Liang-Hao Xia, Tian Liao, Zhuan Li, Zhao-Shen Medicine (Baltimore) 4500 Endoscopic interventional is a commonly used treatment method for idiopathic chronic pancreatitis. Serine protease inhibitor Kazal type 1 (SPINK1) 194+2T>C mutation is most frequently observed in Chinese pancreatitis patients and influences the clinical course of idiopathic chronic pancreatitis patients. We conducted this study to determine the impacts of this mutation on the outcome of endoscopic treatments. In this study, we enrolled 423 patients. Among them, 101 idiopathic chronic pancreatitis patients without other relevant mutations had a successful endoscopic procedure and completed follow-up. Clinical characteristics including Izbicki pain score, exocrine and endocrine function, were evaluated. Genetic sequencing was conducted to detect SPINK1 194+2T>C mutations. The c.194+2T>C mutation was found in 58 (57.43%) patients. Factors relevant to pain relief are c.194+2T>C mutation (P = 0.011), severe pain before treatment (P = 0.005), and necessary subsequent endoscopic treatments (P < 0.001). More patients with the intronic mutation had deteriorated endocrine function (P = 0.001) relative to those patients without the mutation. Patients carrying the c.194+2T>C mutation were less likely to achieve pain relief through endoscopic treatments. They also have a higher risk of endocrine function deterioration. SPINK1 c.194+2T>C mutation may be applied as a pretreatment predictor in idiopathic chronic pancreatitis patients. Wolters Kluwer Health 2015-10-30 /pmc/articles/PMC5058975/ /pubmed/26632706 http://dx.doi.org/10.1097/MD.0000000000002046 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 4500 Sun, Chang Liu, Mu-Yun Liu, Xiao-Gang Hu, Liang-Hao Xia, Tian Liao, Zhuan Li, Zhao-Shen Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis |
title | Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis |
title_full | Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis |
title_fullStr | Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis |
title_full_unstemmed | Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis |
title_short | Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis |
title_sort | serine protease inhibitor kazal type 1 (spink1) c.194+2t > c mutation may predict long-term outcome of endoscopic treatments in idiopathic chronic pancreatitis |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058975/ https://www.ncbi.nlm.nih.gov/pubmed/26632706 http://dx.doi.org/10.1097/MD.0000000000002046 |
work_keys_str_mv | AT sunchang serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis AT liumuyun serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis AT liuxiaogang serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis AT hulianghao serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis AT xiatian serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis AT liaozhuan serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis AT lizhaoshen serineproteaseinhibitorkazaltype1spink1c1942tcmutationmaypredictlongtermoutcomeofendoscopictreatmentsinidiopathicchronicpancreatitis |